AGP Picks
View all

Sci-Tech Europe: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Europe.

Press releases published on July 8, 2026

10x National Security Open-Sources Nexus AI Gateway - an AI Router to enable Enterprise AI Adoption
BPX Launches SAP Signavio Energy & Resources Practice After 40% Faster Close for $1B+ Oil & Gas Operator
Portable vs Wall-Mounted: A Performance Analysis of Lectron Level 2 EV Chargers for Home Use
Geared Power BioTech CEO, Gary Kellstrom, Jr. Featured on 'Going Beyond the Deal' Podcast with J. Michael Fischer, Jr.
UK businesses drastically overestimate their AI progress
ESET Threat Report: AI boosts cyber attackers’ efficiency
Herstel is de benchmark van veerkracht
AMSilk and Ajinomoto Foods Europe Expand Partnership to Enable Industrial-Scale Production of Silk Proteins
The Board Decision Gap: AI Transforms the Deal, But Boards Still Govern the Outcome
On World Obesity Day, WONDERLAB Releases the Targeted Microbiota Weight Management White Paper
New Prop Firm DojoTraders Launches and Aims to Simplify Trading Across Markets
Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
VALLOUREC CONFIRMS ITS INTENTION TO RETURN CLOSE TO €650 MILLION TO SHAREHOLDERS IN 2026 FOLLOWING THE COMPLETION OF ITS SHARE BUYBACK PROGRAM AND THE FULL EXERCISE OF THE WARRANTS
VALLOUREC CONFIRME SON INTENTION DE DISTRIBUER PRES DE 650 MILLIONS D’EUROS A SES ACTIONNAIRES EN 2026 APRES LA FINALISATION DE SON PROGRAMME DE RACHAT D’ACTIONS ET L’EXERCICE INTEGRAL DES BONS DE SOUSCRIPTION D’ACHAT
June 2026 Quarter Production Update
Snail Games 推出《方舟:创世崛起》第一部分、《方舟:命运之潮》及《方舟:龙之乌托邦》DLC;1,100 万美元递延收入积压将于 2026 年第三季度确认
Snail Games 推出《方舟:創世崛起》第一部分、《方舟:財富之潮》及《方舟:龍之烏托邦》可下載內容;遞延收入積壓中的 1,100 萬美元將於 2026 年第三季度確認
Vivani Medical schließt Vereinbarung mit Novo Nordisk zur Evaluierung von NPM-139, einem miniaturisierten, ultra-langwirkenden Semaglutid-Implantat zur langfristigen Gewichtsregulierung
Vivani Medical conclut un accord avec Novo Nordisk pour évaluer le NPM-139, un implant miniature à base de sémaglutide à action ultra-prolongée destiné au traitement de l’obésité
Vivani Medical Mengadakan Perjanjian dengan Novo Nordisk untuk Mengevaluasi NPM-139, Implan Semaglutide Miniatur dengan Kerja Sangat Panjang untuk Pengelolaan Berat Badan Kronis

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Sci-Tech Europe

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.